205 related articles for article (PubMed ID: 24966587)
61. Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Suzuki Y; Kumada H
Drug Des Devel Ther; 2014; 8():869-73. PubMed ID: 25061278
[TBL] [Abstract][Full Text] [Related]
62. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
[TBL] [Abstract][Full Text] [Related]
63. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
[TBL] [Abstract][Full Text] [Related]
64. Two-year data released on Viread for chronic hepatitis B.
AIDS Patient Care STDS; 2008 Nov; 22(11):921. PubMed ID: 19025487
[No Abstract] [Full Text] [Related]
65. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
Liu Y; Wang C; Zhong Y; Chen L; Li X; Ji D; Wang H; Xin S; Zoulim F; Xu D
Antivir Ther; 2010; 15(8):1185-90. PubMed ID: 21149926
[TBL] [Abstract][Full Text] [Related]
66. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
Kim JH; Ahn SH; Ko SY; Choe WH; Kim KH; Kwon SY
Clin Mol Hepatol; 2016 Jun; 22(2):241-9. PubMed ID: 27304549
[TBL] [Abstract][Full Text] [Related]
67. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Tang CM; Yau TO; Yu J
World J Gastroenterol; 2014 May; 20(20):6262-78. PubMed ID: 24876747
[TBL] [Abstract][Full Text] [Related]
68. Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
Galati G; De Vincentis A; Vespasiani-Gentilucci U; Gallo P; Vincenti D; Solmone MC; Dell'Unto C; Picardi A
BMC Gastroenterol; 2014 May; 14():94. PubMed ID: 24885182
[TBL] [Abstract][Full Text] [Related]
69. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
[TBL] [Abstract][Full Text] [Related]
70. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?].
Fuentes Olmo J; Uribarrena Amézaga R
Gastroenterol Hepatol; 2011; 34(7):492-503. PubMed ID: 21550145
[TBL] [Abstract][Full Text] [Related]
71. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
Rijckborst V; Sonneveld MJ; Janssen HL
Aliment Pharmacol Ther; 2011 Mar; 33(5):501-13. PubMed ID: 21198707
[TBL] [Abstract][Full Text] [Related]
72. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827
[TBL] [Abstract][Full Text] [Related]
73. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Leung N
Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
[TBL] [Abstract][Full Text] [Related]
74. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
75. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
76. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
Ha NB; Trinh HN; Rosenblatt L; Nghiem D; Nguyen MH
J Clin Gastroenterol; 2016 Feb; 50(2):169-74. PubMed ID: 26018133
[TBL] [Abstract][Full Text] [Related]
77. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
78. [Management of antiviral-resistant chronic hepatitis B virus infection].
Yim HJ
Korean J Gastroenterol; 2008 Jun; 51(6):346-59. PubMed ID: 18604136
[TBL] [Abstract][Full Text] [Related]
79. Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Ceylan B; Yardimci C; Fincanci M; Eren G; Tozalgan U; Muderrisoglu C; Akkoyunlu Y
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(18):2467-73. PubMed ID: 24089225
[TBL] [Abstract][Full Text] [Related]
80. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Pipili C; Cholongitas E; Papatheodoridis G
Aliment Pharmacol Ther; 2014 Jan; 39(1):35-46. PubMed ID: 24299322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
